Healthcare
BD Capital mulls second fundraising towards end-2023
London-based mid-cap sponsor has crossed the half-way mark of deployment of its debut fund
August Equity announces changes in leadership
Philip Rattle to become chairman with David Lonsdale succeeding him as managing partner
Clean capital: record impact fundraising creates pools of do-good money
Impact vehicles raised EUR 8.5bn last year, but 2023 is off to slow start with just two funds closed
GP Profile: Hayfin seeks European mid-market opportunities with PE strategy
Launched in 2018 and with EUR 1bn AUM, strategy aims to address GPsт need for fund and asset-level capital, partner Gonzalo Erroz tells Unquote
Spex Capital launches EUR 100m early-stage healthtech fund
New GP has sights set on further impact vehicles such as food and climate technology
Hayfin markets USD 500m healthcare-focused private credit fund
New vehicle could back investments such as ARR-based direct loans to high growth businesses
Sullivan Street to strike 'at least' two special sits deals and one exit this year with new ex-ICG hire
First fundraise for the complex situations investor тdefinitelyт on the horizon, although focus now on dealhunting
The Bolt-Ons Digest – 21 February 2023
Unquote’s selection of the latest add-ons with Investindustrial's CEME, Astorg's Fastmarkets, H&F's TeamSystem, and more
Panakès Partners closes second life sciences fund on EUR 175m
GP expects Purple Fund to be good vintage due to lower valuation environment, general partner Alessio Beverina told Unquote
Ardian preps Imes-icore for sale; sellside pitches ongoing
Healthcare tech company could hit the German auction pipeline later this year
BC's VetPartners sees Blackstone, KKR, Partners Group among parties preparing bids
Veterinary group could fetch a valuation in the GBP 2.5bn-GBP 3bn region, having been acquired by BC in 2018
Accession Capital Partners aims for autumn 2023 final close for Fund V
Sponsor has held a EUR 150m first close for its latest fund and will back Central European businesses with flexible capital
Seventure preps third generation of microbiome fund
Health for Life III to be slightly larger than EUR 250m predecessor; will invest in Europe, US, Israel
BlackRock mulls new vintage of private capital products for sophisticated retail investors in Europe
Global asset manager explores new generation of private market funds for wealthy individuals banking on positive uptake from retail investors
LDC outlines plans for new record year of deployment
Despite macro woes, sponsor wants to build up on last yearтs pace of investment and exceed GBP 400m mark in 2023
GP Profile: Key Capital upbeat about SME deals with next fund in the making
UK small-cap sponsor could return to market for its next GBP 125m fund at the end of 2023
21 Invest France eyes EUR 300m Fund VI target by year-end
Fund VI has raised half of its target so far, with the GP seeking to further prove its investment track record throughout 2023
The Bolt-Ons Digest – 26 January 2023
Unquoteтs selection of the latest add-ons, with ICG's Circet, Five Arrows' Mintec, Carlyle's Jagex, and more
German health minister's 'locust sponsors' comments spook live healthcare deals
New entrants scared by remarks on limiting profits; existing investors expected to rush to complete bolt-ons
IK readies Swedish biotech group Mabtech for exit
Jefferies hired as sellside advisor; dual-track process for potential sale or IPO considered
EQT on track for 2023 final close for Fund X
GP has so far raised more than EUR 16bn for the vehicle against EUR 20bn target
Montagu exits Maincare to state-owned Docaposte in off-market deal
Hospital software group considered "missing piece" in buyer's healthcare digitalisation strategy
IK launches mini-cap strategy in UK and Benelux with robust pipeline
With a focus on deals of up to EUR 50m EV, the GP's Development Capital team is in advanced negotiations with several potential targets in the new markets
Inflexion acquires minority stake in Proteros
Deal for German contract research organisation is the sponsor's third in pharma services in past 12 months